Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 218

Protein degradation as a strategy to target mutant WIP1 in ...

Close to 20% of Diffuse Intrinsic Pontine Gliomas (DIPGs) harbor a mutation in a gene called PPM1D that leads to expression of a truncated form of a protein called WIP1. We have found PPM1D-mutant DIPG cells to require expression of WIP1, rendering it an attractive therapeutic target for these ...

Ex-vivo expanded natural killer cells to target DIPG tumor cells ...

Diffuse Intrinsic Pontine Glioma (DIPG) is a rare high-grade glial tumor that occurs in young children and is nearly uniformly fatal. Several factors have contributed to the high fatality in children with DIPG. It occurs in, a region, making surgery potential dangerous. Complete surgical resection of tumor is impossible because ...

PHASE I STUDY OF THE COMBINATION OF VANDETANIB AND DASATINIB ...

Diffuse intrinsic pontine glioma (DIPG) is the most lethal brain tumor in children. Despite treatment with radiation therapy (RT) with or without chemotherapy, the long-term survival of affected children has remained < 10%. Radical surgery is not feasible for children with DIPG. Although RT is the mainstay of therapy, the response ...

MOLECULAR ANALYSIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS

Brainstem gliomas constitute 10 to 15% of all brain tumors in children. Diffuse intrinsic pontine gliomas (DIPG) account for 80% of all brainstem tumors. The treatment of children with DIPG represents a formidable challenge because of the critical location of these tumors, and their refractoriness to therapy. Surgery to confirm the diagnosis is ...

A phase I study of tumor-targetting convection-enhanced delivery for diffuse ...

The paramount goal of the following proposed research is to demonstrate the safety and potential utility of convection-enhanced delivery (CED) in the treatment of children with diffuse pontine glioma. Specifically, this proposal is for a Phase I clinical trial evaluating CED of the targeted radioimmunotherapeutic agent 124I8H9 in children ...